Genetic Technologies (AU:GTG) has released an update.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Rhythm Biosciences Ltd has acquired the Genetype genetic risk assessment business, enhancing its oncology portfolio with an immediate revenue stream and growth potential. This strategic acquisition allows Rhythm to leverage Genetype’s expertise and expand its market presence in both Australia and the US. The integration of Genetype’s technology and team is expected to drive accelerated commercial growth and diversification.
For further insights into AU:GTG stock, check out TipRanks’ Stock Analysis page.